Avid Bioservices Reports Financial Results for First Quarter Fiscal 2019 and Recent Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Avid Bioservices (CDMO) PT Raised to $11 at H.C. Wainwright
September 11, 2018 7:12 AM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Avid Bioservices (NASDAQ: CDMO) to $11.00 (from $6.00) while maintaining a Buy rating.
Pantginis commented, "Yesterday, CDMO reported F1Q19 results, posting EPS of ($0.06), compared with our estimate of ($0.01) and consensus of ($0.13). Revenue for the first quarter was $12.58 million compared with our estimate of $12.87 million and consensus of $8.96 million. Avid ended the quarter with $37.5 million in cash. Management reaffirmed its F2019 revenue guidance of $51-55 million. Under... More
Avid Bioservices (CDMO) Tops Q1 EPS by 3c
September 10, 2018 4:23 PM EDTAvid Bioservices (NASDAQ: CDMO) reported Q1 EPS of ($0.06), $0.03 better than the analyst estimate of ($0.09).
For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.
... More
